Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Short SellingSee which listed companies have disclosed short interest
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Cereno Scientific

0.14 SEK-40.04 %17.11, 17.13
Less than 1K followers

CRNO B

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
-40.04 %
-96.15 %
-97.17 %
-97.47 %
-98.05 %
-98.04 %
-96.92 %
-97.43 %
-97.74 %

Cereno Scientific is a biotechnology company. The company specializes in drug development for common and rare cardiovascular diseases. The lead drug candidate is being developed for the treatment of the rare disease pulmonary arterial hypertension, as well as for thrombotic indications. In particular, epigenetic modulation is used to develop treatments for needy patients with cardiovascular diseases. Cereno Scientific's headquarters are located in Mölndal.

Read more
Market cap
44.04M SEK
Turnover
11.58M SEK
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Financial calendar
15.12
2026

Extraordinary general meeting '26

3.2
2027

Annual report '26

Regulatory press release17.11.2026, 17.11

Cereno Scientific announces resignation of Chairperson of the Board at his own request

Cereno Scientific
Regulatory press release16.11.2026, 22.35

Cereno Scientific announces resignation of Board member at own request

Cereno Scientific
Third party research16.11.2026, 09.54

Cereno Scientific: More runway, more opportunity - Edison

Cereno Scientific has outlined a comprehensive financing package, comprising a proposed SEK400m rights issue and restructuring of its existing SEK175m Fenja debt, marking an important step towards addressing the funding overhang on its clinical programmes...

Cereno Scientific

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release13.11.2026, 08.26

Cereno Scientific provides clarification regarding the trading suspension

Cereno Scientific
Regulatory press release13.11.2026, 08.00

Cereno Scientific gives notice to attend Extraordinary General Meeting

Cereno Scientific
Regulatory press release12.11.2026, 17.20

Cereno Scientific intends to carry out a rights issue of units of approximately SEK 400 million with a focus on the global Phase IIb study EPIMODE and obtains extended loan financing of up to SEK 175 million

Cereno Scientific
Regulatory press release04.11.2026, 07.30

Cereno Scientific Publishes Interim Report for Q3 2026

Cereno Scientific
Press release03.11.2026, 07.30

Cereno Scientific strengthens patient engagement and EPIMODE recruitment foundations at Global PH Summit

Cereno Scientific
Press release02.11.2026, 09.07

Cereno Scientific Sees Strong Investigator Engagement as EPIMODE Phase IIb Trial Advances

Cereno Scientific
Regulatory press release28.10.2026, 12.23

Cereno Scientific AB (publ) publishes report from the Extraordinary General Meeting

Cereno Scientific
Press release16.10.2026, 08.00

Cereno Scientific to Participate at BIO-Europe 2026 as Clinical Pipeline Advances and Strategic Opportunities Expand

Cereno Scientific
Press release09.10.2026, 08.05

Cereno Scientific’s Nomination Committee Proposes Johan Eriksson for Election to the Board of Directors – Experienced Business Leader with Strong Shareholder Commitment

Cereno Scientific
Regulatory press release09.10.2026, 08.00

Cereno Scientific gives notice to attend Extraordinary General Meeting

Cereno Scientific
Press release08.10.2026, 08.30

Cereno Scientific expects up to 15 sites to be activated by year-end 2026 in the global Phase IIb EPIMODE trial; maintains Q4 2028 timeline for topline results

Cereno Scientific
Regulatory press release25.09.2026, 10.14

Cereno Scientific Reports Positive Topline Results from CS014 Phase I PK-bridging Study, Strengthening Intended Direct Path toward Phase IIb in PH-ILD

Cereno Scientific
Press release09.09.2026, 07.30

Cereno Scientific to engage US and international investors at H.C. Wainwright 28th Annual Global Investment Conference in New York

Cereno Scientific
Press release08.09.2026, 07.45

Cereno Scientific to participate at Nordic Life Science Days 2026 as clinical programs advance

Cereno Scientific
Regulatory press release26.08.2026, 08.00

Cereno Scientific Publishes Interim Report for Q2 2026

Cereno Scientific
Third party research17.08.2026, 08.53

Cereno Scientific: CS1 Phase IIb now underway - Edison

Cereno Scientific has launched the global Phase IIb study for CS1 (EPIMODE) in pulmonary arterial hypertension (PAH) with the activation of the first clinical site. We view this as a meaningful execution milestone, clearing the path to patient recruitment...

Cereno Scientific
Press release13.08.2026, 08.00

Cereno Scientific Activates First Clinical Site in Global Phase IIb EPIMODE Trial of CS1 in PAH, Enabling Patient Recruitment

Cereno Scientific